Form 4: Jazz Pharmaceuticals Executive Renee D. Gala Reports Stock Transaction
SEC Form 4 Filing
Renee D. Gala, President & COO of Jazz Pharmaceuticals, reports the disposal of 3,622 ordinary shares to cover tax obligations arising from vesting restricted stock units on March 5, 2024.
Summary
- On March 5, 2024, Renee D. Gala, the President & COO of Jazz Pharmaceuticals, disposed of 3,622 ordinary shares.
- The transaction was executed to satisfy tax obligations related to the vesting of previously granted restricted stock units.
- The shares were disposed of at a price of $117.53 per share.
- Following the transaction, Gala directly owns 57,093 ordinary shares.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations, with no significant impact on the company's outlook.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when restricted stock units vest.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of transaction: Disposal of 3,622 ordinary shares. |
| 03/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.